Biotech Startups

Chime Biologics is a contract development and manufacturing organization (CDMO) that provides end-to-end support for biologics production, from cell line development through clinical and commercial manufacturing. The company launched the Chime AI Platform, which integrates artificial intelligence into discovery, candidate validation, cell line development, and manufacturing for biopharmaceutical partners.

1 investor

Chimera develops engineered cell therapies for cancer that produce therapeutic proteins only upon encountering tumor cells, using natural biological control mechanisms to improve safety and efficacy. The company focuses on treating solid tumors and other currently incurable cancers through localized, controlled immune cell activation.

1 investor

CHONEX develops insect-derived biological products that enhance soil health, plant nutrition, and crop resilience to address challenges including salinity, drought, heat, and nutrient deficiency. The company serves growers by improving root systems and nitrogen use efficiency through a scalable closed-loop biological platform.

1 investor

Chorus Health creates digital healthcare solutions using data, design, and technology to improve patient engagement and outcomes.

1 investor

1 investor

ChromaTan develops biomanufacturing solutions that accelerate product development. The company focuses on manufacturing and biotech applications.

1 investor

Chromis Therapeutics is a biotech company with board members experienced in pharmaceutical development, corporate development, and healthcare investments. The board includes executives with extensive backgrounds in drug discovery, licensing, and biotech operations.

1 investor

1 investor

ChucaoTech develops agrotech and bioinnovation solutions. The company is based in Patagonia, Chile and focuses on supporting SMEs through agricultural technology innovation.

1 investor

Cianna Medical develops oncology products for breast cancer care, including targeted APBI (accelerated partial breast irradiation) therapy and wire-free tumor localization tools for lesions from breast to soft tissue. Its products are aimed at clinicians treating breast cancer patients.

1 investor

Cibus develops crops using a proprietary gene-editing technology that reproduces nature's own genetic blueprints to add specific traits, such as resistance to heat, pests, fungus, and weeds. Working with agricultural partners, it aims to breed seeds faster and produce more resilient, sustainable crops that require fewer chemical inputs.

1 investor

CIGA Healthcare is a family-owned manufacturer of rapid diagnostic and self-test medical devices sold under its Suresign brand to pharmacies, health services, and retailers in over 70 countries. It supplies over-the-counter, professional, and veterinary diagnostic tests and runs an R&D program covering digital readers, spectroscopy, and disease testing.

1 investor

CIMA manufactures intraocular lenses (IOLs) and optical devices designed for cataract surgery and vision correction. The company produces IOLs using advanced biocompatible materials with features like aspheric optics, square edges, and blue light filtering for patients undergoing cataract procedures.

1 investor

CimCure develops active cancer vaccines that use its proprietary Immune-Boost (iBoost) technology to prompt the body to produce antibodies that attack and destroy the blood vessels feeding solid tumours, stopping cancer growth. Founded as a spin-off from the Angiogenesis Laboratory at Amsterdam UMC, the biotech company targets all types and stages of solid tumours.

1 investor

Cimico develops biotechnology solutions for municipal and industrial wastewater treatment, centered on its energy-efficient MBBR (MOBED) technology and the Helinia digital platform for monitoring, advanced control, and digital twin. It also offers the FILMATH mathematical simulation tool and serves sectors such as food processing, textiles/laundries, refineries, and small seasonal municipalities.

1 investor

CIMPLRX discovers and develops drug candidates using its own explainable AI platform, CEEK-CURE, which builds machine learning models for target- and compound-based hit identification, lead optimization, and mechanism-of-action analysis. It serves biotech and pharmaceutical companies with tools to design new compounds, screen chemical libraries, and visualize the drug discovery process.

1 investor

CinderBio develops HTA-Proteases, specialized enzymes for proteomics research that enable comprehensive protein analysis through orthogonal digestion approaches. The company serves life sciences and biotech researchers requiring advanced tools for protein characterization and mass spectrometry applications.

1 investor

CINV is a pharmaceutical-grade botanical therapeutics platform that cultivates, processes, and distributes regulated plant-derived medicines and standardised APIs, with medical cannabis (CBPMs) as its core product. It operates a vertically integrated seed-to-patient supply chain and clinical research program, serving patients through licensed distribution partners across the UK and Europe.

1 investor

Circe Scientific provides DMPK (drug metabolism and pharmacokinetics) and PK/PD consulting for biotech, pharmaceutical, and venture capital clients working in drug discovery and development. It supports research projects across inhaled, dermal, and oral drug delivery routes.

1 investor

Circulate Health provides therapeutic plasma exchange (TPE) treatments for longevity care, offering science-based clinical interventions to extend healthspan. The company enables clinics to deliver TPE services to patients and conducts research to advance the clinical evidence base for longevity medicine.

1 investor

Circumvent develops precision medicines for neurodegenerative diseases, with current focus on Batten Disease and other rare neurological disorders. The company's research targets synaptic dysfunction and lysosomal pathways through investigation of the palmitoylome.

1 investor

Cirqle is developing a hormone-free, on-demand contraceptive that uses a molecule to reinforce the natural cervical mucus barrier and block sperm. The technology is in pre-clinical development and targets women seeking non-hormonal birth control options.

1 investor

MLM Medical Labs (which acquired CirQuest Labs) provides central and specialty laboratory services for global clinical trials, including clinical testing, biomarker assay development, clinical trial kit building, sample analysis, and biological sample storage. It serves biotech and pharmaceutical companies developing drugs, operating central labs in Germany and Memphis, Tennessee.

1 investor

Cirrus Therapeutics is a biotech developing gene and cell therapies based on ocular immunology to treat dry age-related macular degeneration (AMD), including an AAV gene therapy to restore the IRAK-M immune regulator and a next-generation retinal pigment epithelium (RPE) cell therapy for advanced geographic atrophy. It serves patients with chronic blinding eye diseases and operates from Cambridge, Massachusetts and Singapore.

1 investor